The 2002/3 Canadian Cardiovascular Society consensus guideline update for the diagnosis and management of heart failure.

The Canadian medical community in general, and the Canadian Cardiovascular Society (CCS) in particular, have played a major role in promoting evidencebased clinical practice in Canada. The Heart Failure Guideline Consensus Panel of the CCS published one of the first national guidelines on the clinical evidence for the diagnosis and treatment of heart failure in 1994 and published a comprehensive update in The Canadian Journal of Cardiology in December 2001.

[1]  J. McMurray,et al.  Angiotensin receptor blockers in heart failure , 2003, Journal of the renin-angiotensin-aldosterone system : JRAAS.

[2]  N. Hollenberg,et al.  Literature alert , 2002 .

[3]  Milton Packer,et al.  Cardiac resynchronization in chronic heart failure. , 2002, The New England journal of medicine.

[4]  R. Kerber,et al.  ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices , 2002 .

[5]  J. Cohn,et al.  Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. , 2002, Journal of the American College of Cardiology.

[6]  R. Kerber,et al.  ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). , 2002, Circulation.

[7]  G. Habib,et al.  Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. , 2002, Circulation.

[8]  D. Levy,et al.  Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. , 2002, JAMA.

[9]  K. Dickstein,et al.  Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial , 2002, The Lancet.

[10]  Alan S Maisel,et al.  Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. , 2002, The New England journal of medicine.

[11]  Thomas Lavergne,et al.  Long-term benefits of biventricular pacing in congestive heart failure: results from the MUltisite STimulation in cardiomyopathy (MUSTIC) study. , 2002, Journal of the American College of Cardiology.

[12]  Simon Stewart,et al.  Home-Based Intervention in Congestive Heart Failure: Long-Term Implications on Readmission and Survival , 2002, Circulation.

[13]  D. Delurgio,et al.  Cardiac resynchronization in chronic heart failure. , 2002, The New England journal of medicine.

[14]  M. Redfield,et al.  The potential of brain natriuretic peptide as a biomarker for New York Heart Association class during the outpatient treatment of heart failure. , 2002, Journal of cardiac failure.

[15]  J. Cahill,et al.  Heart failure management: multidisciplinary care has intrinsic benefit above the optimization of medical care. , 2002, Journal of cardiac failure.

[16]  James B. Young.  Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: A randomized controlled trial , 2002 .

[17]  K. Kuck,et al.  Primary Prevention of Sudden Cardiac Death in Idiopathic Dilated Cardiomyopathy: The Cardiomyopathy Trial (CAT) , 2002, Circulation.

[18]  J. Oss,et al.  PROPHYLACTIC IMPLANTATION OF A DEFIBRILLATOR IN PATIENTS WITH MYOCARDIAL INFARCTION AND REDUCED EJECTION FRACTION , 2002 .

[19]  R. McKelvie,et al.  Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials. , 2002, Journal of the American College of Cardiology.

[20]  Sheldon H Gottlieb,et al.  A randomized trial of the efficacy of multidisciplinary care in heart failure outpatients at high risk of hospital readmission. , 2002, Journal of the American College of Cardiology.

[21]  Harlan M Krumholz,et al.  Randomized trial of an education and support intervention to prevent readmission of patients with heart failure. , 2002, Journal of the American College of Cardiology.

[22]  P. Poole‐Wilson.  Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. , 2002 .

[23]  K. Dickstein,et al.  Effects of losartan and captopril on mortality and morbidity after acute myocardial infarction: The OPTIMAAL randomized trial. , 2002 .

[24]  Wojciech Zareba,et al.  Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. , 2002, The New England journal of medicine.

[25]  D. Tepper.  Randomized trial of an education and support intervention to prevent readmission of patients with heart failure. , 2002, Congestive heart failure.

[26]  J. Cohn,et al.  A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. , 2001, The New England journal of medicine.

[27]  J. McMurray,et al.  Randomised controlled trial of specialist nurse intervention in heart failure , 2001, BMJ : British Medical Journal.

[28]  Thomas Lavergne,et al.  Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay , 2001 .

[29]  J. Daubert,et al.  Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. , 2001, The New England journal of medicine.

[30]  L. Lenert,et al.  A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. , 2001, Journal of the American College of Cardiology.

[31]  L. Lenert,et al.  Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. , 2001, Journal of the American College of Cardiology.

[32]  C. Frampton,et al.  Treatment of heart failure guided by plasma amino-terminal brain natriuretic peptide (N-BNP) levels improves outcome , 2000 .

[33]  B. Riegel,et al.  Which patients with heart failure respond best to multidisciplinary disease management? , 2000, Journal of cardiac failure.

[34]  M. Pfeffer,et al.  Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. , 2000, American heart journal.

[35]  A. Feldman,et al.  Heart failure management using implantable devices for ventricular resynchronization: Comparison of Medical Therapy, Pacing, and Defibrillation in Chronic Heart Failure (COMPANION) trial. COMPANION Steering Committee and COMPANION Clinical Investigators. , 2000, Journal of cardiac failure.

[36]  T. LeJemtel,et al.  Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. , 2000, The New England journal of medicine.

[37]  K. Lee,et al.  Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sudden death. Multicenter Unsustained Tachycardia Trial Investigators. , 2000, The New England journal of medicine.

[38]  S. Connolly,et al.  Long term management of the survivor of ventricular fibrillation or sustained ventricular tachycardia. , 2000, The Canadian journal of cardiology.

[39]  Bertram Pitt,et al.  Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II , 2000, The Lancet.

[40]  C. Frampton,et al.  Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations , 2000, The Lancet.

[41]  Orton,et al.  INTRAVENOUS NESIRITIDE, A NATRIURETIC PEPTIDE, IN THE TREATMENT OF DECOMPENSATED CONGESTIVE HEART FAILURE , 2000 .

[42]  Ric,et al.  ELECTROPHYSIOLOGIC TESTING TO IDENTIFY PATIENTS WITH CORONARY ARTERY DISEASE WHO ARE AT RISK FOR SUDDEN DEATH , 2000 .

[43]  K. Lee,et al.  A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. , 1999, The New England journal of medicine.

[44]  B. Jonathan.  Comprehensive discharge planning and home follow-up of hospitalized elders: A randomized clinical trial , 1999 .

[45]  Simon Stewart,et al.  Effects of a multidisciplinary, home-based intervention on planned readmissions and survival among patients with chronic congestive heart failure: a randomised controlled study , 1999, The Lancet.

[46]  M. Pfeffer,et al.  Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators. , 1999, Journal of cardiac failure.

[47]  Robert Luke,et al.  Harrison's Online , 1999, J. Educ. Technol. Soc..

[48]  L. Erhardt,et al.  Cost effective management programme for heart failure reduces hospitalisation , 1998, Heart.

[49]  C. Frampton,et al.  Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. , 1998, Circulation.

[50]  H. Tunstall-Pedoe,et al.  Biochemical detection of left-ventricular systolic dysfunction , 1998, The Lancet.

[51]  Bertram Pitt,et al.  Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) , 1997, The Lancet.

[52]  R. Carney,et al.  A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. , 1995, The New England journal of medicine.

[53]  A. Richards,et al.  Plasma brain natriuretic peptide in assessment of acute dyspnoea , 1994, The Lancet.